The Hippo pathway is a central regulator of organ size and tissue homeostasis. Hippo kinases and adaptor proteins mediate the phosphorylation and inactivation of YAP and TAZ, two closely related transcription coactivators. The Hippo pathway responds to a variety of extracellular and intracellular signals, spanning from cell-cell contact and mechanical cues to ligands of G-protein-coupled receptors and metabolic avenues. In some instances, YAP/TAZ activation is tuned by forces that bypass the Hippo kinase module, adding further complexity to the biology of the pathway. Over the past two decades, the Hippo pathway has increasingly been connected with developmental processes and tissue repair, being intimately tied to the function of tissue-specific progenitor cells. Pervasive activation of YAP/TAZ has been recognized in a multitude of human tumors and connected with the acquisition of malignant traits, including resistance to anticancer therapies, distant dissemination and maintenance of cancer stem cells. On this ground, Hippo-related biomarkers are increasingly investigated in translational studies striving to identify prognostic and predictive factors. In addition, the dependency of many tumors on YAP/TAZ may be exploited for therapeutic purposes. Albeit no direct inhibitors are currently available, drug repositioning approaches provided hints that YAP/TAZ inhibition can be achieved with old drugs, such as cholesterol-lowering agents or compounds blocking bone resorption.
resulted in a similar outcome, leading to the functional and biochemical characterization of the "Salvador-Warts-Hippo" (SWH) pathway. Since inactivating mutations of the aforementioned genes promoted hyperproliferation and reduced apoptosis, with consequent tissue overgrowth and onset of tumors, the SWH pathway was designated as a tumor suppressor signaling in fly tissues. The transcriptional coactivator Yorkie (yki), the downstream effector of the pathway, was discovered in 2005 in a screen of Wts-interacting proteins (Huang, Wu, Barrera, Matthews, & Pan, 2005) . Yki was found to be phosphorylated and inactivated by Wts, and its overexpression phenocopied hpo, sav, and wts loss-of-function mutations. As Yki does not contain any DNAbinding domain, the final piece of the puzzle in the regulation of pathway-responsive genes was the identification of the TEA-domain transcription factor Scalloped (Sd) (Wu, Liu, Zheng, Dong, & Pan, 2008; Zhang et al., 2008) .
Mammalian homologs of SWH pathway components, such as the transcriptional co-factor Yes-associated protein (YAP) (Sudol, 1994) and its paralog transcriptional co-activator with PDZ-binding motif (TAZ) (Kanai et al., 2000) , were already known before the functional characterization of the pathway in Drosophila. Nevertheless, studies in flies have been instrumental in delineating the architecture and function of the mammalian Hippo pathway (Dong et al., 2007) . Ever since, the Hippo pathway has gained increasing popularity, its deregulation was observed in a variety of tumors and linked to a number of tumorpromoting activities. Importantly, with the exception of NF2, Hippo pathway mutations have sporadically been detected in cancer genome studies, indicating the functional nature of pathway perturbation in human tumors (Zanconato, Cordenonsi, & Piccolo, 2016) . Thus, aberrant YAP/TAZ activation in cancer is mainly driven by a combination of several inputs that physiologically regulate their function, but that are dysfunctional in tumors.
In this review, we first provide an overview of the Hippo pathway together with the complex molecular network that tunes its activation/inactivation, we then discuss its involvement in developmental processes, and finally summarize evidence on aberrant pathway activity in neoplastic diseases together with potential therapeutic opportunities.
Regulation of the Hippo pathway
The hearth of the mammalian Hippo signaling encompasses the serine/threonine kinases sterile 20-like kinase 1 and 2 (MST1 and MST2; Hpo in Drosophila) and large tumor suppressor 1 and 2 (LATS1 and LATS2, Wts in Drosophila). Hippo kinases, in cooperation with the scaffold proteins Salvador homolog 1 (SAV1; Sav in Drosophila) and MOB kinase activator 1A and 1B (MOB1A and MOB1B; Mats in Drosophila), phosphorylate and inhibit the Hippo transducers YAP and TAZ (Yki in Drosophila). In such a manner, the Hippo core module prevents YAP/ TAZ nuclear accumulation and interaction with the TEA domaincontaining sequence-specific transcription factors (TEAD1 to TEAD4, Sd in Drosophila). Beyond TEAD factors, YAP/TAZ also cooperate with other transcriptional partners including SMADs, T-box transcription factor 5 (TBX5) and RUNT-related transcription factors (RUNX1 and RUNX2) (Halder & Johnson, 2011) . Thus, the phosphorylation cascade mediated by the Hippo core module refrains YAP/TAZ-driven gene transcription by promoting their nuclear exclusion, cytoplasmic retention and proteasomal degradation (Dong et al., 2007; Lei et al., 2008; Liu et al., 2010; Zhao et al., 2007; Zhao, Li, Tumaneng, Wang, & Guan, 2010) . When the regulatory module is inactivated, or in the presence of stimuli that activate YAP/TAZ independently on Hippo kinases, Hippo transducers accumulate into the nucleus where, upon interaction with transcriptional partners, mediate the transcription of target genes (i.e. CTGF, CYR61, ANKRD1, BIRC5, AXL) (Piccolo, Dupont, & Cordenonsi, 2014) . Recently, it has been observed that YAP/TAZ also function as transcriptional co-repressors in a process that requires TEAD factors and recruitment of the nucleosome-remodeling and histone deacetylase (NuRD) complex. This leads to transcriptional repression of tumor-suppressor genes, such as DNA-damage-inducible transcript 4 (DDIT4) and TNF-related apoptosis-inducing ligand (TRAIL), ultimately favoring the activity of mechanistic target of rapamycin complex 1 (mTORC1) (Kim, Kim, Johnson, & Lim, 2015) .
A complex network regulates Hippo signaling. A variety of different molecular inputs, spanning from cell polarity and cell adhesion mechanisms to mechanical cues, metabolic pathways and soluble factors modulate YAP/TAZ activation (Piccolo et al., 2014) . In turn, regulation of the Hippo signaling is controlled by a negative-feedback loop, since YAP/ TAZ mediate the transcription of Hippo kinases and other negative pathway regulators (Chen, Wang, Xu, Guo, & Jiang, 2015; Dai et al., 2015; Mohseni et al., 2014 Mohseni et al., , 2015 . In addition, YAP/TAZ modulate the expression of ligands controlling the activity of a number of pathways, such as sonic hedgehog (SHH), Wnt, transforming growth factor β (TGF-β) and Notch, delineating their involvement in an extensive crosstalk governing cell fate via both autocrine and paracrine mechanisms (Yu, Meng, Plouffe, & Guan, 2015) .
Stimuli regulating the Hippo signaling in mammals can be schematically grouped in: i) determinants of cell polarity and cell-cell junctions. These include apicobasal cell polarity (ABCP) proteins, such as Scribble (SCRIB), which promote the activation of Hippo kinases Mohseni et al., 2014) , and factors that sequester YAP/TAZ including the apical crumbs complex (CRB) (Varelas et al., 2010) , angiomotin family (AMOTs), which can either sequester YAP/TAZ Wang, Huang, & Chen, 2011; Zhao et al., 2011) or activate the Hippo pathway (Adler et al., 2013; Hirate et al., 2013) , and protein tyrosine phosphatase non-receptor type 14 (PTPN14) Wang et al., 2012) ; ii) factors mediating the activation of Hippo kinases, such as KIBRA, neurofibromin 2 (NF2, also known as Merlin), and TAO (thousand and one amino acid protein) kinases (Boggiano, Vanderzalm, & Fehon, 2011; Genevet, Wehr, Brain, Thompson, & Tapon, 2010; Poon, Lin, Zhang, & Harvey, 2011; Xiao, Chen, Ji, & Dong, 2011; Yin et al., 2013; Yu et al., 2010) ; iii) mechanical cues (mechanotransduction), such as extracellular matrix stiffness and changes in cell geometry, attachment status and density (Aragona et al., 2013; Dupont et al., 2011; Wada, Itoga, Okano, Yonemura, & Sasaki, 2011) . These mechanical forces regulate the Hippo pathway by modulating Rho GTPases and remodeling of the actin cytoskeleton; iv) soluble factors that act through G-protein-coupled receptors (GPCRs) and Rho GTPases. Hormones and growth factors can either activate (lysophosphatidic acid, thrombin, angiotensin II and estrogen) or inhibit (epinephrine and glucagon) YAP/TAZ (Kim, Kim, Lee, Huang, et al., 2013; Miller et al., 2012; Mo, Yu, Gong, Brown, & Guan, 2012; Wennmann et al., 2014; Yu et al., 2012; Yu, Hu, et al., 2013; Zhou et al., 2015) . Another level of ligand-dependent regulation of YAP/TAZ refers to the Hippo-Wnt pathway cooperation. This model envisions the incorporation of YAP/TAZ into the β-catenin destruction complex (Azzolin et al., 2014) . In the absence of Wnt signaling, YAP/TAZ participate in β-catenin degradation. Conversely, stimulation by Wnt ligands disassembles the destruction complex, promoting both YAP/TAZ-and β-catenin-mediated gene transcription; v) metabolic pathways promoting YAP/TAZ nuclear localization (mevalonate pathway) or their binding to TEAD factors (glucose metabolism and aerobic glycolysis) (DeRan et al., 2014; Enzo et al., 2015; Mo et al., 2015; Sorrentino et al., 2014; Wang et al., 2015) . Control of YAP/TAZ operated by the mevalonate pathway involves Rho GTPases, as geranylgeranyl pyrophosphate, produced in the mevalonate cascade, is required for correct membrane anchoring of Rho GTPases. Fig. 1 illustrates the Hippo cascade and its regulatory branches.
The Hippo pathway in organ development
The idea that the Hippo pathway plays a central role in organ development is rooted in pioneering studies in Drosophila, unveiling how mutations of Hippo pathway kinases or Yki overexpression led to the overgrowth of various organs and appendages (Harvey et al., 2003; Huang et al., 2005; Jia et al., 2003; Justice et al., 1995; Kango-Singh et al., 2002; Lai et al., 2005; Pantalacci et al., 2003; Tapon et al., 2002; Udan et al., 2003; Wu et al., 2003; Xu et al., 1995) . A wave of studies exploiting conditional knockout alleles and inducible transgenic mice later revealed that the effects of the Hippo pathway on cell proliferation and stem cell fate, and ultimately tissue overgrowth and tumorigenesis, are conserved in mammals.
Digestive system
The first clues that Hippo-mediated organ size control is conserved in mammals date back to 2007, when two independent reports described an increase in liver mass upon transgenic Yap expression (Camargo et al., 2007; Dong et al., 2007) . This process was related to proliferation of mature hepatocyte, and molecularly tied to the transcription of genes promoting hepatocyte proliferation together with negative regulators of apoptosis. Hepatomegaly was a reversible phenomenon, as the liver returned to its original size when Yap overexpression was turned off. Prolonged YAP overexpression resulted in the onset of liver nodules with characteristics of hepatocellular carcinoma (HCC), a finding consistent with the imbalance in proliferation/apoptosis. YAPinduced liver overgrowth and tumorigenesis was later found to be dependent on TEAD-mediated gene responses, as hepatomegaly and tumorigenesis were suppressed by a small molecule inhibiting TEAD-YAP association (verteporfin), or by a dominant-negative TEAD2 molecule (Liu-Chittenden et al., 2012) . Liver enlargement and tumorigenesis were also observed with liver-specific knockout of Mst1 and Mst2, Lats1 and Lats2, Sav1, Nf2 and Mob1A/1b (Benhamouche et al., 2010; Lee et al., 2010; Lu et al., 2010; Nishio et al., 2016; Song et al., 2010; Yin et al., 2013; Zhang et al., 2010; Zhou et al., 2009 ). The observed phenotype was connected, at the cellular level, with an increased proliferative capacity of oval cells, a population of bipotential progenitors capable of differentiating into either hepatocytes or ductal cholangiocytes. This is in line with the observations that mice developed, in some instances, both HCC and cholangiocarcinoma (or bile duct hamartoma). Alternatively, the onset of both HCC and cholangiocarcinoma in Hippo mutant mice was reconnected with the dedifferentiation of hepatocytes into cells carrying progenitor characteristics (Yimlamai et al., 2014) . In addition, it has been recently proposed that activation of YAP/TAZ induced by loss of Lats1/2 triggers the differentiation of hepatoblasts and hepatocytes into biliary epithelial cells . Overall, it is plausible that cell fate determination in the liver depends on a precise spatiotemporal regulation of the Hippo pathway and YAP/TAZ. The YAP-mediated proliferative transcriptional program is involved in liver repair after injury (i.e. partial hepatectomy or cholestatic liver injury) (Bai et al., 2012; Grijalva et al., 2014; Herr et al., 2014; Su et al., 2015; Yimlamai et al., 2014) . Consistently, the pharmacological inhibition of MST1/2 was proposed for enabling liver repair and regeneration . Prolonged YAP activity also fuels activation of hepatic stellate cells, leading to liver fibrosis (Mannaerts et al., 2015) .
In the intestine, Yap overexpression generated intestinal dysplasia without affecting the size of the organ. Expression of endogenous YAP was restricted to the progenitor/stem cell compartment residing at the bottom of the intestinal crypts Camargo et al., 2007) . Consequently, its activation expanded multipotent undifferentiated progenitors that replaced differentiated cell types (i.e. enterocytes, mature goblet cells and Paneth cells). The conditional knockout of Sav1 and Mst1/2 also resulted in the expansion of progenitor cells in a YAPdependent manner Lee et al., 2008; Zhou, Hao, et al., 2011) . Interestingly, while the YAP/TAZ-TEADs cooperation was required for the proliferation of intestinal stem/progenitor cells, the interaction of YAP/TAZ with the transcription factor KLF4 promoted differentiation into goblet cells, plausibly operating at the level of secretory progenitors (Imajo, Ebisuya, & Nishida, 2015) . Unpredictably, in 2013 Barry and colleagues reported an unexpected growth-suppressive function of YAP. Transgenic expression of Yap provoked a rapid loss of intestinal crypts by repressing the Wnt signalling, whereas Yap loss promoted Wnt hypersensitivity after irradiation, leading to crypt cell proliferation (Barry et al., 2013) . These conflicting results may derive from differences in the experimental models, YAP-mediated negative feedback regulation Dai et al., 2015; Moroishi et al., 2015) , and the complex connection between YAP/TAZ and the Wnt pathway. Indeed, two recent studies described YAP/TAZdependent intestinal crypt overgrowth in a background of adenomatous polyposis coli (APC) deficiency, albeit via different molecular mechanisms. The first model proposed the incorporation of YAP/TAZ in the β-catenin destruction complex (Azzolin et al., 2014) . When the Wnt pathway is inactive, YAP/TAZ participate in β-catenin degradation. Conversely, Wnt ligand stimulation releases YAP/TAZ from the complex favoring nuclear accumulation of both β-catenin and YAP/TAZ. On this ground, it has been hypothesized that YAP/TAZ may act as both mediators and inhibitors of the Wnt pathway. The second model envisions that APC, a key negative regulator of β-catenin, functions as a scaffold protein facilitating YAP/TAZ phosphorylation and inhibition via Hippo kinases (Cai, Maitra, Anders, Taketo, & Pan, 2015) . Overall, these lines of evidence pointed to an intricate Hippo-Wnt crosstalk in intestinal development and regeneration, and bring to light the need for further investigations to better delineate this relationship. Further highlighting the role of YAP in intestinal homeostasis and regulation of stem cell fate, YAP activity was found to be essential for intestinal regeneration after injury Gregorieff et al., 2015; Kim et al., 2017; Taniguchi et al., 2015) . Given the close connection between uncontrolled tissue regeneration and malignant transformation, YAP activation promoted the development of Apc-deficient adenomas Camargo et al., 2007; Gregorieff et al., 2015) , and constitutive YAP activity induced by the inflammatory mediator prostaglandin E2 (PGE2) led to formation of polyps and colon cancers .
The Hippo signalling in pancreatic development and homeostasis deserves a final mention. Mst1/2 deletion unexpectedly resulted in a reduction of the pancreas size, a phenotype related to pancreatitis-like autodigestion consequent to defective formation of ductal structures (Gao et al., 2013; George, Day, Boerner, Johnson, & Sarvetnick, 2012) . Defects in the Hippo pathway mainly affected the exocrine compartment.
Heart, lung and kidney
Heart enlargement was reported with inactivation of Sav1, Mst1 and Mst2, and Lats2 (Heallen et al., 2011; Song et al., 2010) . Likewise, cardiomyocytes hyperproliferation with consequent enlargement of the heart was observed with Yap overexpression (Del Re et al., 2013; von Gise et al., 2012; Xin et al., 2011) , whereas its inactivation resulted in lethal heart hypoplasia (von Gise et al., 2012; Xin et al., 2011) similar to earlier reports with Tead1 knockouts (Chen, Friedrich, & Soriano, 1994; Sawada et al., 2008) . Genetic ablation of Hippo pathway components determined an increased expression of nuclear β-catenin and up-regulation of Wnt target genes, determining cardiomyocytes proliferation via YAP/β-catenin interaction (Heallen et al., 2011) . In the adult heart, inactivation of Hippo kinases/adaptors (Heallen et al., 2013) or forced Yap expression (Del Re et al., 2013; Lin, von Gise, et al., 2014; Xin et al., 2013) promoted heart regeneration and improved cardiac function in myocardial infarction models. YAP-mediated activation of the PI3K-AKT pathway and cytoskeletal remodeling were described as mechanisms promoting heart regeneration (Lin, Yao, & Chuang, 2015; Morikawa et al., 2015) . Of note, Yap overexpression promotes proliferation of satellite cells, the resident stem cells of skeletal muscle, promoting muscle hypertrophy (Judson et al., 2012; Watt et al., 2015) . YAP activity increases after degeneration of motor nerves as a mechanism to mitigate neurogenic muscle atrophy (Watt et al., 2015) .
The first line of evidence highlighting the involvement of the Hippo pathway in lung development and function stemmed from studies investigating the effects of Taz inactivation (Makita et al., 2008; Mitani et al., 2009) . Adult mice displayed abnormal alveolar structures with an emphysema-like phenotype. This morphological picture seemed independent of TTF1, a crucial factor in branching morphogenesis requiring TAZ for the production of the surfactant protein C (Park et al., 2004) . It was later revealed that loss of Mst1/2 disrupted lung structures resulting in neonatal lethality Lange et al., 2015; Lin, Zhou, et al., 2015) , and that conditional deletion of Mst1/2 from bronchiolar epithelial cells in the mature lung induced progressive airway hyperplasia (Lange et al., 2015) . Moreover, YAP emerged as a crucial factor in airway stem cell biology (Mahoney, Mori, Szymaniak, Varelas, & Cardoso, 2014; Zhao et al., 2014) . Zhao et al. reported that, after Yap deletion, the adult basal stem cell pool was markedly reduced due to an uncontrolled differentiation and, at the histological level, the normal pseudostratified airway epithelium was simplified into a columnar epithelium (Zhao et al., 2014) . Conversely, Yap overexpression induced stem cell self-renewal and inhibited terminal differentiation, promoting epithelial stratification and hyperplasia. Moreover, YAP regulates proximal-distal patterning of the lung and proper airway morphogenesis by inducing Sox2 expression and enabling epithelial progenitors to properly respond to TGF-β stimulation (Mahoney et al., 2014) .
Inactivation of Yap or Taz in the kidney resulted in different phenotypes: while Taz inactivation determined polycystic kidney disease (Hossain et al., 2007; Makita et al., 2008; Tian et al., 2007) , YAP was found to be required for nephron morphogenesis (Reginensi et al., 2013) . This process was linked to the Rho GTPase Cdc42, which controls YAP activity. Indeed, defects in nephrogenesis observed upon Cdc42 ablation phenocopied Yap loss. At the molecular level, Cdc42 ablation decreased nuclear localization of YAP and reduced the expression of YAP-responsive genes (Reginensi et al., 2013) . YAP and TAZ are also essential for the development of the lower urinary tract (Reginensi et al., 2015) and in branching morphogenesis . Moreover, podocyte-specific Yap deletion resulted in podocyte apoptosis with consequent proteinuria and histological features of focal segmental glomerulosclerosis (Schwartzman et al., 2016) . Even though Sav1 and Mst1/2 knockout kidneys appeared unaffected (Reginensi et al., 2013; Song et al., 2010) , more recent studies showed that Sav1 deficiency promoted YAP-dependent proliferation of renal tubular epithelial cells with formation of both glomerular and tubular cysts (Kai et al., 2016) , and that dual deletion of Lats1 and Lats2 disrupted nephrogenesis by impairing maintenance and differentiation of nephron progenitor cells (McNeill & Reginensi, 2017) . Finally, increased transcriptional activity of YAP was implicated in renal compensatory hypertrophy in a rat model of uninephrectomy, and in kidney regeneration after acute injury (Domínguez-Calderón et al., 2016; Xu et al., 2016) . On the other hand, constant activation of YAP and TAZ was tied to kidney fibrosis, raising the hypothesis that their activation should be finely modulated for therapeutic purposes (Seo et al., 2016; Szeto et al., 2016; Xu et al., 2016) .
Other organs and systems
Activation of YAP or Sav1 deletion lead to skin thickening, as a result of the expansion of basal progenitor cells (Camargo et al., 2007; Lee et al., 2008; Schlegelmilch et al., 2011; Zhang, George, et al., 2011) . However, neither Mst1/2 nor Lats1/2 inactivation influenced YAP activation, suggesting the existence of a yet unappreciated control mechanism (Schlegelmilch et al., 2011; Silvis et al., 2011) . Long-term activation of YAP, or Mob1a/1b deletion, resulted in skin cancers (Iglesias-Bartolome et al., 2015; Nishio et al., 2012; Schlegelmilch et al., 2011; Silvis et al., 2011) , and deletion of Yap and Taz impaired regeneration after wounding (Elbediwy et al., 2016; Lee, Ran Byun, Furutani-Seiki, Hong, & Jung, 2014) . Evidence supporting the involvement of YAP in brain development stemmed from studies investigating the effects of Nf2 inactivation. Absence of Nf2 determined an overexpansion of neural progenitor cells, resulting in severe malformation of the hippocampus in mice. This process was mediated by YAP activation in a Hippo pathway-independent manner (Lavado et al., 2013) . NF2-YAP signaling is also involved in the development of the corpus callosum and dorsal root ganglia (Lavado, Ware, Pare´, & Cao, 2014; Serinagaoglu, Paré, Giovannini, & Cao, 2015) . Regarding the breast, Yap, Taz and Sav1 seemed dispensable in mammary gland development but, rather, are implicated in post-natal changes such as those occurring during pregnancy or in the post-pubertal period Skibinski et al., 2014) . A final mention deserves the immune-related, non-canonical Hippo/MST pathway. In this field, MST1/2 kinases operate via different downstream effectors, and their activity is essential for immune homeostasis and immunological self-tolerance. The Hippo/MST pathway controls a number of T cell functions including development, activation, survival, trafficking, and homing (Du, Yu, & Tao, 2015) .
The Hippo pathway in cancer
Aberrant activation of YAP/TAZ has been reported in various human tumors and linked to a plethora of tumor-promoting functions, spanning from invasion and metastasis to therapeutic resistance and maintenance of the cancer stem cell (CSCs) pool. Remarkably, activated YAP/ TAZ confers resistance to both chemotherapeutics (Bartucci et al., 2015; Cordenonsi et al., 2011) and molecular targeted agents such as BRAF-, MEK-and HER2-directed agents Lin, Yao, & Chuang, 2015; Lin, Zhou, et al., 2015) . Activation of YAP via mechanotransduction is also required for maintaining cancerassociated fibroblasts (CAF) and their tumor-enhancing functions, indicating that YAP/TAZ promote oncogenic functions even by controlling the tumor-stroma interplay (Calvo et al., 2013) . Consistently with the widespread deregulation of YAP/TAZ observed in functional studies, increased expression of YAP/TAZ and signature denoting their activation have been associated with adverse clinical outcomes in cancer patients.
Breast cancer
TAZ expression has frequently been reported in different breast cancer (BC) subtypes, where its expression is associated with aggressive clinical, pathological and molecular features (triple-negative tumors, elevated Ki-67 levels, high grade, stem cell signatures), inferior survival outcomes and decreased efficacy of neoadjuvant (presurgical) therapy (Bartucci et al., 2015; Cordenonsi et al., 2011; Díaz-Martín et al., 2015; Skibinski et al., 2014; Vici et al., 2014 Vici et al., , 2016 . Increased TAZ expression in basal-like BC compared with other subtypes may be related to a TAZ-induced luminal to basal lineage switch, which requires an interaction with components of the SWI/SNF chromatin-remodeling complex (Skibinski et al., 2014) . Expression of Hippo transducers, together with their targets (CTGF and AXL) and regulators (HMG-CoA reductase), was also observed in male BC, one of the rarest tumors arising in men (Di Benedetto et al., 2016a , 2016b .
Mechanistically, overexpression of TAZ induced oncogenic transformation of non-neoplastic mammary cells via the interaction with TEAD factors and the disruption of Hippo kinase-mediated control (Chan et al., 2008 Zhao, Zhi, Zhou, & Chen, 2012) . Moreover, an oncogenic program requiring YAP/TAZ, TEADs and SMAD2/3 was described as a way BC cells use to overcome the tumor-suppressive effect of TGF-β in early oncogenic phases (Hiemer, Szymaniak, & Varelas, 2014) . Overexpression of TAZ in BC cell lines also promotes invasive and migratory properties (Chan et al., 2008; Yang et al., 2012) , and drives the establishment and progression of bone metastases Matteucci et al., 2013) . Novel insights into the multifaceted tumor-promoting role of TAZ have been provided by investigations specifically looking for molecular factors governing the BC stem cell (BCSC) compartment. TAZ promotes self-renewal and tumor-forming ability of BCSCs, enabling them to withstand chemotherapy and to distantly disseminate (Bartucci et al., 2015; Cordenonsi et al., 2011) . Different molecular circuits account for the TAZ-mediated acquisition/retention of CSCs features, including EMT-mediated delocalization of Scribble with the consequent alleviation of TAZ inhibition , the cooperation between TAZ and hypoxiainducible factor 1 (HIF-1) (Xiang et al., 2014 (Xiang et al., , 2015 , and the interaction between laminin 511 matrix and α6Bβ1 integrin that promotes TAZ nuclear localization .
While both experimental and clinical evidence converge in assigning oncogenic functions to TAZ, some discrepancies exist regarding YAP. On the one hand, YAP overexpression in non-transformed mammary epithelial cells or BC cell lines induced EMT, proliferation, anchorageindependent growth and metastatic proclivity Lamar et al., 2012; Overholtzer et al., 2006; Wang et al., 2014; Zhang et al., 2009) . Moreover, in a mouse model of oncogene-induced BC, Yap knockout delayed the onset of mammary tumors, reducing metastasis formation . On the other hand, different lines of evidence point to YAP as a tumor-suppressive factor: i) YAP stabilizes p73 inducing the transcription of pro-apoptotic genes (Danovi et al., 2008; Levy, Adamovich, Reuven, & Shaul, 2007; Strano et al., 2001 Strano et al., , 2005 , ii) YAP is phosphorylated and inhibited by oncogenic Akt (Basu, Totty, Irwin, Sudol, & Downward, 2003) , iii) YAP is located at 11q22.2, a site of frequent loss of heterozygosity in BC (Carter et al., 1994; Gudmundsson et al., 1995) , iv) functional studies described increased malignant features upon YAP knockdown in BC cell lines Yuan et al., 2008) , and v) some inconsistencies exist when comparing studies investigating the clinical significance of YAP expression in BC (Kim, Jung, & Koo, 2014; Lehn et al., 2014; Sheen-Chen et al., 2012; Vici et al., 2016) . Speculatively, it is possible that YAP elicits different functions in relation to the underlying genetic background of BC, and consequently in the different intrinsic subtypes. For instance, YAP interacts with mutant p53 inducing a transcriptional program that accelerates cell cycle progression (Di Agostino et al., 2016) . Moreover, YAP expression should be analyzed in the different cellular compartments (e.g. tumor and stromal cells), in order to consider its involvement in the tumor-stroma crosstalk (Calvo et al., 2013; Vici et al., 2016) .
Gastrointestinal tumors
YAP/TAZ knockdown in human colorectal cancer (CRC) cell lines suppressed growth, hindered tumor-forming ability and limited metastatic dissemination after injection in mice (Azzolin et al., 2012; Pan et al., 2012; Rosenbluh et al., 2012; Wang et al., 2013; Yuen et al., 2013) . YAP depletion decreased proliferation and survival in CRC cells in a process accompanied by reduced β-catenin and Notch signaling (Zhou, Hao, et al., 2011) . In turn, YAP expression in CRC cells is driven by β-catenin/TCF4, and a YAP-TBX5-β-catenin transcriptional complex promotes the transcription of anti-apoptotic genes in β-catenindependent CRC cells (Avruch, Zhou, & Bardeesy, 2012; Konsavage, Kyler, Rennoll, Jin, & Yochum, 2012; Rosenbluh et al., 2012) . Overall, these findings point to a reciprocal interaction between YAP and the Wnt pathway in CRC. Further increasing the complexity of pathway crosstalk mediating YAP/TAZ function in CRC, endothelin receptor A (ETAR) was found to trigger proliferation and tumorigenicity of CRC cells via GPCRs and Rho GTPases, with consequent suppression of the Hippo pathway and transcriptional activation of YAP/TAZ . Moreover, YAP overexpression rescued cell viability of KRAS-dependent CRC (and lung cancer) cells after KRAS suppression, and KRAS and YAP establish an oncogenic cooperation that converges on the transcription factor FOS to induce EMT (Shao et al., 2014) . Finally, attenuation of malignant features in CRC cells was reported with miR-195-5p-mediated YAP repression . Elevated expression of YAP/TAZ in biological samples from CRC patients was associated with poor survival outcomes and reduced efficacy of chemotherapy in retrospective case series (Kim, Kim, Lee, Kuninaka, et al., 2013; Touil et al., 2014; Wang et al., 2013; Yuen et al., 2013) . Interestingly, a signature denoting YAP activation confers inferior progression-free survival in advanced CRC patients with KRAS wild-type disease treated with cetuximab monotherapy (Lee et al., 2015) .
In esophageal cancer cells, YAP over-activation installs CSC features by up-regulating SOX9, and feeds chemoresistance through increased EGFR expression (Song et al., , 2015 . YAP expression was associated with more aggressive clinical-pathological characteristics (e.g. Ki-67 levels, histological grade, stage) and adverse clinical outcomes (Muramatsu et al., 2011; Yeo et al., 2012; Zhao et al., 2016) . YAP-mediated oncogenic functions were also described in gastric cancer (GC), both in functional assays and in biological specimens (Kang et al., 2011) . YAP knockdown hindered cell proliferation, invasion, and motility of GC cells, and nuclear YAP expression conferred inferior disease-specific survival (Kang et al., 2011) . Disruption of the YAP-TEAD interaction with a Vgl-like-4-(VGLL4) mimicking peptide suppressed tumor growth both in vitro and in vivo (Jiao et al., 2014) .
In pancreatic ductal adenocarcinoma (PDAC), YAP promotes the proliferation of mutant KRAS cells and induces the expression of genes encoding secretory factors, ultimately promoting the pro-tumorigenic stromal response that characterizes PDAC . In addition, the YAP/TEAD2 complex drives an oncogenic program essential for the maintenance of KRAS-independent PDAC (Kapoor et al., 2014) . The idea that YAP functions as a central oncogenic force in non-KRAS-driven PDAC has been further confirmed in a mouse model of chronic inflammation (Swidnicka-Siergiejko et al., 2016) . Consistently with the oncogenic role of YAP in PDAC, disruption of the YAP-TEAD interaction hindered tumor growth, promoted apoptosis, and inhibited angiogenesis and vasculogenic mimicry (Wei et al., 2017) , whereas its hyper-activation confers chemoresistance . Finally, activation of TAZ induces proliferative and migratory properties to pancreatic cancer cells .
The connection between deregulated Hippo signaling and human liver tumorigenesis has widely been documented with genetically engineered mouse models (Benhamouche et al., 2010; Camargo et al., 2007; Dong et al., 2007; Lee et al., 2010; Liu-Chittenden et al., 2012; Lu et al., 2010; Song et al., 2010; Yimlamai et al., 2014; Yin et al., 2013; Zhang et al., 2010; Zhou et al., 2009) . A number of factors plausibly account for the increased YAP activity and the consequent onset of HCC and bile duct cancer, including YAP amplification (Zender et al., 2006) , carcinogenic compounds (Kowalik et al., 2011) , interaction with hepatitis B virus proteins , and defects in bile acid homeostasis (Anakk et al., 2013) . Mechanistically, tumorenhancing functions of YAP/TAZ in liver cancer have been connected with activation of Notch signaling, together with an up-regulation of amino acid transporters, increased uptake of amino acids and ultimately mTORC1 activation Tschaharganeh et al., 2013) . Moreover, the YAP-TEAD complex mediates a positive feedback loop by inducing the expression of miR-130a that, in turn, represses the YAP antagonist VGLL4 . Therapeutically, blocking the YAP-TEAD interaction hinders YAP-mediated HCC (Liu-Chittenden et al., 2012) , and YAP inhibition achieved with a small interfering RNA-lipid nanoparticles was proposed as a differentiation-inducing therapy (Fitamant et al., 2015) . More recently, Hippo signal deficiency and YAP activation were connected with polyploid cell division and genomic instability via Akt signaling . From a clinical perspective, YAP and TAZ expression have been associated with inferior survival outcomes in HCC patients Kim, Kim, & Park, 2013; Xu et al., 2009) . Likewise, signatures denoting inactivation of the Hippo pathway and YAP-induced chromosome instability seem to confer adverse survival outcomes (Sohn et al., 2016; Weiler et al., 2017) .
Thoracic tumors
The Hippo pathway has been implicated in the biology of non-small cell lung cancer (NSCLC), which accounts for approximately 85% of lung cancers. Inhibition of YAP/TAZ in NSCLC cells suppresses cell proliferation, induces cell cycle arrest, reduces tumorigenicity and increases sensitivity to EGFR-directed therapies (Dubois et al., 2016; Hsu et al., 2016; Lau et al., 2014; Lin et al., 2013; Lo Sardo et al., 2017; Noguchi et al., 2014; Xu et al., 2013 Xu et al., , 2015 Zhang, Nandakumar, et al., 2014; Zhou, Zhang, et al., 2011) . YAP/TAZ also sustain selfrenewal of NSCLC stem cells, partly through a metabolic control operated by stearoyl-CoA-desaturase 1 (SCD1), an enzyme involved in monounsaturated fatty acids synthesis (Bora-Singhal et al., 2015; Noto et al., 2017) . YAP was found to inhibit squamous transdifferentiation of LAC , and its overexpression accelerates the progression of lung adenocarcinoma (LAC) in the Kras G12D lung cancer mouse model (Zhang, Gao, et al., 2015) . Furthermore, a screening of synthetic-lethal genetic interaction in KRAS-mutant NSCLC cells revealed a selective sensitivity of these cells to the inhibition of the nuclear transport receptor XPO1 . Nevertheless, a subset of KRAS-mutant cell lines was intrinsically resistant to XPO1 inhibition as a consequence of YAP activation, further highlighting the YAP-dependent resistance mechanism to KRAS inhibition. Functional studies are complemented by clinical data suggesting that increased protein-level expression of YAP/TAZ, gene signatures mirroring their activity, and decreased expression of LATS1/2 are associated with poor clinical outcomes Lin, Zhang, Wu, Qiu, & Wang, 2014; Noguchi et al., 2014; Wang et al., 2010; Xie et al., 2012) . While deregulated Hippo pathway also promotes malignant pleural mesothelioma Mizuno et al., 2012; Tanaka et al., 2017; Tranchant et al., 2016; Zhang, Dai, et al., 2017) , YAP/TAZ activation defines a subset of small cell lung cancer (SCLC) with atypical features such as adherent cell morphology, lower expression of neuroendocrine markers, increased chemosensitivity and better prognosis (Horie, Saito, Ohshima, Suzuki, & Nagase, 2016; Ito et al., 2016) . Thus, YAP/TAZ supposedly play an opposite role in NSCLC and SCLC.
Genitourinary and gynecologic tumors
YAP activation induces age-related prostate cancer (PC) in mice . YAP interacts with the androgen receptor (AR) and positively regulates AR signaling, mediating a switch from an androgen-sensitive to an androgen-insensitive state (Kuser-Abali, Alptekin, Lewis, Garraway, & Cinar, 2015; Zhang, Yang, et al., 2015) . These findings are supported by YAP analysis in tissue samples, conveying the message that increased YAP activity may represent a mechanism conferring resistance to androgen-deprivation therapy (Sheng et al., 2015; Zhang, Yang, et al., 2015) . Moreover, YAP contributes to the establishment of a tumor-supportive microenvironment by inducing the production of the chemokine CXCL5 that, in turn, attracts CXCR2-expressing myeloid-derived suppressor cells . Likewise, in PC cells TAZ promotes cell migration, EMT and induces CSC features Liu, Yu, Huang, Cui, & Hong, 2017) . Recent studies also suggested a central role of Hippo kinases in refraining YAP/TAZ activation in PC. For instance, α3β1 integrin was found to restrain Rho GTPase activity, thereby supporting tumor-suppressive functions of the Hippo pathway (Varzavand et al., 2016) , whereas the molecular chaperone heat shock protein 27 accelerates proteasomal degradation of MST1, leading to nuclear accumulation of YAP (Vahid, Thaper, Gibson, Bishop, & Zoubeidi, 2016) .
The contribution of deregulated Hippo pathway in the pathobiology of renal cancer is less clear, owing to the paucity of functional studies. Nevertheless, molecular characterization efforts revealed that NF2 mutations, and deregulation of the Hippo pathway, are fairly common in mucinous tubular and spindle cell carcinoma, and in renal cell carcinomas with unclassified histology (Chen, Xie, Huang, & Yang, 2016; Mehra et al., 2016) . YAP activation confers cisplatin resistance in urothelial cell carcinoma, and its nuclear expression is associated with inferior survival outcomes in patients with urothelial cell carcinoma treated with perioperative chemotherapy (Ciamporcero et al., 2016) .
As mentioned for liver cancer, emerging evidence points to the role of viral oncoproteins in mediating YAP activation. Human papilloma virus (HPV) infection is the leading cause of cervical cancer, owing to the ubiquitin-mediated degradation of p53 and pRb mediated by the HPV proteins E6 and E7. HPV E6 protein has also been found to prevent proteasome-dependent YAP degradation, fuelling cervical cancer cell proliferation . Clinically, nuclear TAZ expression was associated with reduced pathological complete response rate in cervical cancer patients treated with neoadjuvant chemotherapy (Buglioni et al., 2016) .
YAP and TAZ overexpression in ovarian cancer (OC) cell lines increases cell proliferation, induces EMT and confers chemoresistant features Hall et al., 2010; Xia et al., 2014; Yagi et al., 2016; Zhang, Pasolli, & Fuchs, 2011) . Constitutive YAP activation induces malignant transformation through increased secretion of fibroblast growth factor1/2 and epidermal growth factor (EGF)-like ligands, and thereby stimulation of their cognate receptors (He, Mao, et al., 2015; Hua et al., 2016) . Two studies recently described miRmediated control of YAP/TAZ. In particular, two miRs, namely miR-129-5p and miR-509-3p, were found to repress YAP/TAZ and attenuate malignant features Tan et al., 2015) . Elevated nuclear YAP expression, increased expression of TAZ mRNA, and a gene expression signature reflecting YAP activation have consistently been correlated with poor clinical outcomes in OC patients (Chen, Xu, et al., 2016; Cho et al., 2017; Hall et al., 2010; Jeong et al., 2014; Zhang, Pasolli, et al., 2011) . Of note, YAP seems implicated in the biology of granulosa cell tumors, which accounts for ∼70% of all malignant sex-cord stromal tumors. YAP overexpression promotes proliferation, migration and steroidogenesis in granulosa cell tumor cell lines, and nuclear YAP expression was more frequently observed in tumor tissues compared with their normal counterparts (Fu et al., 2014) .
Melanoma, primary brain tumors and sarcomas
YAP-dependent growth of uveal melanoma cells has been reported as a consequence of mutations in the GNAQ oncogene (Feng et al., 2014; Yu et al., 2014) . According to this model, GNAQ-induced tumorigenesis and YAP activation was reconnected to the regulation of the actin cytoskeleton by Rho GTPases. Importantly, inhibition of the YAP-TEAD4 interaction by verteporfin efficiently targeted uveal melanoma cells carrying gain-of-function GNAQ mutations. From a therapeutic perspective, it is important to note that some discrepancies exist regarding YAP/TAZ activation in relation to BRAF mutations. Indeed, while Yu et al. reported that YAP is suppressed in BRAF-mutant cells , Nallet-Staub and colleagues suggested that in cutaneous melanoma YAP/TAZ oncogenic functions are independent of the underlying BRAF mutational status (Nallet-Staub et al., 2014) . Moreover, remodeling of the actin cytoskeleton and YAP/TAZ activation have been recently connected with resistance to pharmacological inhibition of BRAF in BRAFmutant melanoma cells . Further supporting this argument, a genetic screen in BRAF-mutant tumor cells revealed that YAP mediates resistance to BRAF and MEK inhibitor therapy, whereas YAP silencing enhanced the antitumor efficacy of vemurafenib (BRAF inhibitor) and trametinib (MEK inhibitor) in melanoma xenografts . Unexpectedly, it has recently been reported that inactivation of LATS1/2 in melanoma cells induced a host anti-tumor immune response that suppresses tumor growth (Moroishi et al., 2016) . LATS1/2 deletion in tumor cells stimulates the secretion of nucleic-acid-rich extracellular vesicles that elicit a type I interferon response. This, in turn, stimulates multiple cellular components involved in the immune-mediated elimination of cancer cells.
Finally, attenuation of the Hippo signaling and YAP/TAZ-mediated gene transcription confer aggressive molecular features in glioblastoma multiforme (Artinian et al., 2015; Lignitto et al., 2013; Orr et al., 2011; Xu, Stamenkovic, & Yu, 2010; Yang et al., 2016) , and YAP has been designated as an oncogene in osteosarcoma (Basu-Roy et al., 2015; Chan et al., 2014) , embryonal rhabdomyosarcoma (Tremblay et al., 2014) and soft-tissue sarcomas (Eisinger-Mathason et al., 2015) 4.6. Targeting the Hippo pathway for anticancer therapy Functional studies conveyed the message that blocking YAP/TAZmediated transcription may be an effective treatment for various tumors. Even though no specific inhibitors are currently available, screening of approved drugs revealed that compounds already in use for various medical conditions may target YAP/TAZ (Fig. 2) . In a screening of more than 3300 Food and Drug Administration (FDA)-approved drugs, porphyrin molecules, which are used as photodynamic therapy in macular degeneration, emerged as the most potent compounds inhibiting TEAD-YAP association, thus efficiently counteracting YAPinduced liver overgrowth (Liu-Chittenden et al., 2012) . Verteporfin treatment also effectively killed uveal melanoma cells carrying Gq/11 mutations . Next, the G protein-coupled β-adrenergic receptor agonist dobutamine, an inotropic agent used for acute heart failure, was found to promote the recruitment of YAP to the cytosol, thus hindering YAP-dependent gene transcription (Bao et al., 2011) . These effects were unrelated to the activation of Hippo kinases, as knocking down LATS1 and LATS2 did not affect dobutamine-induced YAP phosphorylation. Also the BCR-ABL inhibitor dasatinib inhibits YAP (Rosenbluh et al., 2012) . Again, inhibitory effects on YAP occurred independently on Hippo kinases, but were rather due to dasatinibmediated inhibition of YES1. This, in turn, interfered with the assembly of a YAP-β-catenin-TBX5 complex mediating the proliferation of β-catenin-dependent CRC cells. Statins, the popular cholesterol-lowering medications, inhibit YAP/TAZ in a LATS1/2-independent manner (Sorrentino et al., 2014) . At the biochemical level, statin-mediated inhibition of YAP/TAZ is related to the inhibition of HMG-CoA reductase, the rate-limiting enzyme of the mevalonate pathway. HMG-CoA reductase inhibition causes a reduction of geranylgeranyl pyrophosphate, with the consequent altered membrane tethering of Rho GTPases (protein prenylation). Similar effects were reported with nitrogen-containing bisphosphonates (N-BPs), compounds administered for the treatment of osteoporosis and the prevention of skeletal-related events in cancer patients. N-BPs (i.e. zoledronic acid) act on the mevalonate pathway by inhibiting farnesyl pyrophosphate synthase, thus interfering with protein prenylation. Finally, the antidiabetic agent metformin was found to inhibit YAP. At the molecular level, metformin activates AMP-activated protein kinase (AMPK) that, in turn, inhibits YAP via both LATS activation and direct YAP phosphorylation (Mo et al., 2015) .
Conclusions
Research over the past decade provided considerable insights into the way the Hippo signaling govern organ development and tissue regeneration. Moreover, overwhelming functional evidence shed light on the multifaceted way through which YAP/TAZ promote oncogenic transformation and boost tumor progression. In spite of this, a number of questions still remain unanswered. Since the earliest evidence emerged that Hippo-mediated size control is not a universal mechanism, as not all organs are equally affected by pathway manipulation. Specific tissue contexts, requirements of signals acting upstream the Hippo cascade, Hippo-independent control of YAP/TAZ and/or mechanical inputs may account for these differences. On this ground, further tailored investigations are needed to elucidate the different molecular networks that converge on the Hippo pathway for regulating the development of various organs. In the field of regenerative medicine, YAP/ TAZ activation was advocated as essential for tissue repair after acute, and in some instances chronic, tissue damage. In most cases, YAP/TAZdriven regeneration was connected to the activation of tissue-resident adult stem/progenitor cells. However, prolonged YAP/TAZ activity culminated into fibrosis, as observed in liver and kidney (Mannaerts et al., 2015; Seo et al., 2016; Szeto et al., 2016; Xu et al., 2016) . Paradoxically, signaling pathways inducing stem cell proliferation may also provoke stem cell exhaustion and depletion, if persistently activated. This implies that therapeutic exploitation of YAP/TAZ manipulation for regenerative purposes might necessitate from an alternation of activatory and inhibitory stimuli in order to enable tissue repair while avoiding fibrotic degeneration. Regarding tumors, a number of intertwined factors deserve attention to accelerate the preclinical-clinical transition of Hippo biomarkers and YAP/TAZ-targeting agents. While YAP/TAZ activation seems to be a shared trait across a constellation of tumor types, differences plausibly exist in the forces that drive their activity, and in the way they interact with and respond to genetically defective pathways. From a clinical prospective, achieving a deeper understanding of this inter-tumor variability is instrumental for the development of both Hippo biomarkers predicting the efficacy of anticancer therapies (and/or survival outcomes), and YAP/TAZ-directed therapeutics. In the first case, namely the identification of prognostic/predictive markers, attempts which have been carried out so far relied on the assessment of individual molecular endpoints in retrospective case series. We envision that this process may be streamlined with the generation of more sophisticated assays that, for instance, also take into account upstream and "lateral" pathway regulators, constitutively activated signals that intersect the Hippo cascade (e.g. mutated Wnt pathway components, KRAS mutations), together with the molecular output of YAP/TAZ transcription (i.e. target genes). Obtaining a more exhaustive picture of the processes underlying improper YAP/TAZ activation may increase the chances to successfully validate Hippo signatures in prospective and adequately powered studies. Similar considerations can be extended when considering YAP/TAZ as therapeutic targets. In this case, two critical factors deserve consideration: i) YAP/TAZ modulation has been obtained only indirectly, as aforementioned in the previous section, and ii) YAP/TAZ inhibition does not probably configure the targeting of an oncogenic addiction, as mutations in key pathway components have uncommonly been reported. Trial designs specifically ideated for assessing pathway modulation upon exposure to a given treatment may help overcome these hurdles. For example, window-ofopportunity trials rely on the administration of a given compound in the period elapsing between diagnosis and surgical resection (Maugeri-Saccà et al., 2016) , thus offering the advantage of pre-and post-therapy tissue collection for extensive molecular analysis. Testing putative YAP/TAZ inhibitors (e.g. statins, bisphosphonates, metformin) in window-of-opportunity trials may provide a wealth of information, including efficient YAP/TAZ targeting (e.g. decreased expression, increased phosphorylation, decreased expression levels of target genes), together with an estimate of anti-tumoral effects elicited by their inhibition (e.g. down-staging, anti-proliferative activity as assessed by Ki-67 reduction). In conclusion, over the past years considerable steps forward have been made in understanding Hippo pathway biology; how to transfer these notions to the clinical setting is the challenge ahead.
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